Novavax Inc
NVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001000694
No open-market purchases or sales by Novavax Inc insiders were filed in the last 90 days; 267 institutions reported holding it in 13F filings for Q2 2026, worth $1.11B in total; Coatue Management is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +10 vs. previous quarter
- 267
- 13F valueReported value at the end of Q2 2026
- $1.11B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding NVAX, Q2 2026
1 superinvestor reports holding Novavax Inc on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
Open-market purchases and sales by Novavax Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 2, 2025 (view filing) | Dec 13, 2024 | 20 daysLate | King Rachel K.Director | SSale | −4.15K | $9.02 | −$37.4K | −21.9%14.8K after | |
| Jan 2, 2025 (view filing) | Dec 24-31, 2024 | 9 daysLate | Young James FDirector | SSale | −10.0K | $8.22 | −$82.2K | −16.2%51.8K after | 2 lots |
| Jun 25, 2024 (view filing) | Jun 21 | 4 days | Young James FDirector | SSale | −7.50K | $14.09 | −$105.7K | −10.8%61.8K after | |
| Jun 21, 2024 (view filing) | Jun 18 | 3 days | Young James FDirector | SSale | −7.50K | $13.72 | −$102.9K | −9.8%69.3K after | 2 lots |
| Jun 20, 2024 (view filing) | Jun 17 | 3 days | Dubovsky FilipPresident, R&D | SSale | −13.9K | $14.47 | −$201.2K | −17.3%66.6K after | 2 lots |
| May 15, 2024 (view filing) | May 14 | 1 day | Dubovsky FilipPresident, R&D | SSale | −47.3K | $13.90 | −$657.6K | −54.8%39.0K after | |
| Mar 14, 2023 (view filing) | Mar 6-10 | 8 daysLate | Glenn Gregory MPresident, R&D | PPurchase | +6.00K | $7.17 | +$43.0K | +70.8%14.5K after | 3 lots |
| Apr 4, 2022 (view filing) | Mar 31 | 4 days | Young James FDirector | SSale | −12.5K | $73.58 | −$919.8K | −16.6%62.6K after | 3 lots |
| Jan 5, 2022 (view filing) | Jan 3 | 2 days | Herrmann John A IIIEVP, Chief Legal Officer | SSale | −5.00K | $140.91 | −$704.5K | −56.5%3.85K after | 8 lots |
| Jan 4, 2022 (view filing) | Dec 31, 2021 | 4 days | Young James FDirector | SSale | −3.75K | $144.16 | −$540.6K | −4.8%75.1K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Novavax Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Shah Capital Management | 14,165,577 | $133.4M | 25.36% | −679,520−4.6% | Reduced |
| BlackRock, Inc. | 13,946,881 | $131.4M | 0.00% | +1,102,562+8.6% | Added |
| State Street Corp | 11,740,550 | $110.6M | 0.00% | +2,770,032+30.9% | Added |
| Vanguard Portfolio Management LLC | 7,607,996 | $71.7M | 0.00% | +456,371+6.4% | Added |
| Vanguard Capital Management LLC | 7,257,449 | $68.4M | 0.00% | +127,302+1.8% | Added |
| Sanofi | 6,880,481 | $64.8M | 12.14% | 00.0% | Unchanged |
| D. E. Shaw & Co., Inc. | 5,650,905 | $53.2M | 0.03% | −2,058,953−26.7% | Reduced |
| Geode Capital Management, LLC | 4,207,370 | $39.6M | 0.00% | +308,957+7.9% | Added |
| Two Sigma Investments, LP | 4,091,043 | $38.5M | 0.03% | +3,476,244+565.4% | Added |
| Coatue Management LLCSuperinvestorCoatue Management | 3,836,986 | $36.1M | 0.07% | 00.0% | Unchanged |